VOR vs VSTM

Vor Biopharma Inc. vs Verastem, Inc. — Valuation Comparison 2026

VOR

Biotechnology
Vor Biopharma Inc.
Quality
3.5
out of 10
Value Trap
30
LOW
Price
$15.01
Last close
Models
7/13
Active
VS

VSTM

Biotechnology
Verastem, Inc.
Quality
5.8
out of 10
Value Trap
24
SAFE
Price
$4.29
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType VOR Fair ValueVOR Upside VSTM Fair ValueVSTM Upside
Bayesian DCF Intrinsic $5.72 -61.9% $2.00 -53.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.73 -80.8% $2.19 -48.9%
PWERM Option-Based $25.80 +71.9% $5.28 +23.1%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VOR vs VSTM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VOR vs VSTM — Which Stock Is More Undervalued?

VSTM scores higher with a 5.8/10 quality rating vs VOR's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vor Biopharma Inc. (VOR) and Verastem, Inc. (VSTM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VOR currently trades at $15.01 with a QOC of 3.5/10, while VSTM trades at $4.29 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).